Senzo, a Life Sciences company, based in Philadelphia, PA, announces their partnership with BARDA, an arm of the Administration for Strategic Preparedness and Response (ASPR), in the US Department of Health and Human Services (HHS) to secure FDA approval for their innovative new diagnostic test.
Senzo’s Amplified Lateral Flow (ALF) test is a true lateral flow device, requiring no additional equipment, yet returning the same accuracy (sensitivity and specificity) as a laboratory-based PCR test across multiple diseases including Covid-19, Flu A/B, RSV, TB, HIV, Hep-C, and C.Diff.
This news follows both a study by the University of Sheffield corroborating their claims of 100% ALF to PCR agreement and a subsequent $2m private market investment.
Oct 24, 2022